Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the first ...
For pediatric patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), residential fine particulate matter (PMâ‚‚.â‚… ...
A new review explains how targeted immunotherapies are stripping predictive power from traditional risk markers in adult ...
ZYNLONTA is a CD19-directed antibody-drug conjugate approved by the U.S. FDA and conditionally approved by the European Commission for certain patients with relapsed or refractory DLBCL after two or ...
ADC Therapeutics SA announced that its Japanese licensing partner, Tanabe Pharma Corporation, filed a marketing authorization application with Japan's Ministry of Health, Labor and Welfare on October ...
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer diagnosis ...
About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our ...
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell ...
Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...
B cell subsets contribute to long-term tumor control and improved overall patient survival in multiple tumor types.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results